Press releases

September 23, 2020 Regulatory
IRLAB Therapeutics has been approved for listing on Nasdaq Stockholm Main Market

September 10, 2020
IRLAB’s drug candidate pirepemat featured on cover of top-tier journal JPET

August 26, 2020 Regulatory
IRLAB delårsrapport januari – juni 2020

August 3, 2020
IRLABs IRL752 föreslås få det unika INN-namnet pirepemat av WHO

August 3, 2020
IRLAB’s IRL752 is proposed pirepemat as a unique INN by WHO

July 9, 2020
IRLAB:s kliniska läkemedelskandidat IRL752 publicerad i JPET

July 9, 2020
IRLAB’s clinical drug candidate IRL752 published in JPET

June 24, 2020
IRLAB’s mesdopetam featured on cover of top-tier publication JPET

June 24, 2020
IRLABs mesdopetam presenteras på omslaget av topprankade vetenskapliga tidskriften JPET

June 4, 2020
IRLAB:s Fas IIb/III-studie vid Parkinsons sjukdom inriktas mot god rörelseförmåga

June 4, 2020
IRLAB’s Phase IIb/III study in Parkinson’s disease to target Good ON

May 7, 2020 Regulatory
Kommuniké från årsstämma 2020 i IRLAB Therapeutics AB

May 7, 2020 Regulatory
Report from the Annual General Meeting of IRLAB Therapeutics AB

May 7, 2020
Ordförandens brev till aktieägarna i IRLAB Therapeutics inför årsstämman 2020

May 7, 2020
IRLAB publicerar video av VD-presentationen och förbereder livesändning av årsstämman 2020

May 7, 2020 Regulatory
IRLAB delårsrapport januari – mars 2020

May 6, 2020
IRLAB:s kliniska läkemedelskandidat mesdopetam publicerad i JPET

May 6, 2020
IRLAB’s clinical drug candidate mesdopetam published in JPET

April 24, 2020
IRLAB erbjuder förhandsröstning på årsstämman

April 7, 2020 Regulatory
IRLAB publicerar årsredovisning för 2019

April 7, 2020 Regulatory
IRLAB publishes the annual report for 2019

April 7, 2020 Regulatory
IRLAB kallar till stämma den 7 maj 2020

March 23, 2020
IRLAB:s Fas IIa-studie med IRL752 publiceras i Movement Disorders

March 23, 2020
IRLAB’s Phase IIa study with IRL752 is published in Movement Disorders

February 27, 2020
IRLAB:s företrädesemission övertecknad

February 27, 2020
IRLAB’s rights issue oversubscribed

February 7, 2020 Regulatory
IRLAB offentliggör prospekt avseende företrädesemissionen

February 7, 2020 Regulatory
IRLAB publishes prospectus relating to the rights issue

February 6, 2020
IRLAB lanserar ny webbplats

February 6, 2020 Regulatory
IRLAB bokslutskommuniké 2019

February 4, 2020
IRLAB’s IRL790 receives new name ‘mesdopetam’

February 4, 2020
IRLAB:s IRL790 får nya namnet ’mesdopetam’

December 12, 2019 Regulatory
IRLAB has carried out a directed issue of SEK 70 million and resolves on a rights issue of approximately SEK 145 million

December 12, 2019 Regulatory
IRLAB har genomfört en riktad emission om 70 MSEK och beslutar om företrädesemission om cirka 145 MSEK

December 12, 2019 Regulatory
IRLAB intends to make a capital raise of approximately SEK 215 million

December 12, 2019 Regulatory
IRLAB avser att genomföra en kapitalanskaffning om cirka 215 MSEK

November 7, 2019 Regulatory
IRLAB delårsrapport januari – september 2019

November 6, 2019
IRLAB’s drug candidates IRL942 and IRL1009 have been granted patents in the US and Europe

November 6, 2019
IRLAB:s läkemedelskandidater IRL942 och IRL1009 har beviljats patent i USA och Europa

October 21, 2019
IRLAB is presenting at the Society for Neuroscience 2019 Neuroscience conference

October 21, 2019
IRLAB presenterar vid Society for Neuroscience 2019 års Neuroscience conference

October 17, 2019 Regulatory
Nomination committee in IRLAB appointed

October 17, 2019 Regulatory
Valberedningen i IRLAB utsedd

September 26, 2019
IRLAB’s IRL790 is proposed a unique INN by WHO

September 26, 2019
IRLAB:s IRL790 föreslås få unikt INN av WHO

September 23, 2019
IRLAB presents at the 2019 International Congress of Parkinson’s Disease and Movement Disorders

September 23, 2019
IRLAB presenterar på 2019 års ’International Congress of Parkinson’s Disease and Movement Disorders’

August 28, 2019 Regulatory
IRLAB delårsrapport januari – juni 2019

August 28, 2019
IRLAB to advance clinical development of IRL790 in LIDs based on in-depth analysis of positive Phase IIa results

August 28, 2019
IRLAB fortsätter klinisk utveckling i LIDs med IRL790 baserat på fördjupad analys av positiva Fas IIa-resultat

July 15, 2019 Regulatory
IRLAB reports top line results from Phase IIa study with IRL790

July 15, 2019 Regulatory
IRLAB rapporterar top line-resultat från Fas IIa studie med IRL790

May 28, 2019
IRLAB and research consortium awarded MSEK 2.9 Vinnova grant

May 28, 2019
IRLAB och forskningskonsortium tilldelas Vinnova bidrag på 2,9 MSEK

May 27, 2019
Today, May 27, is the last day of trading in IRLAB’s share before share split

May 27, 2019
Idag, den 27 maj, är sista dag för handel i IRLAB:s aktie före aktiesplit

May 17, 2019 Regulatory
IRLAB announces share split

May 17, 2019 Regulatory
IRLAB genomför aktiesplit

May 9, 2019
IRLAB completes recruitment for its Phase II study with IRL790 in Parkinson’s disease patients with dyskinesia

May 9, 2019
IRLAB slutför rekrytering till Fas II-studien med IRL790 för Parkinsons sjukdomspatienter med dyskinesi

April 25, 2019 Regulatory
IRLAB – Resolutions at Annual General Meeting 2019

April 25, 2019 Regulatory
IRLAB – beslut vid årsstämma 2019

April 25, 2019 Regulatory
IRLAB delårsrapport januari-mars 2019

April 3, 2019 Regulatory
IRLAB Therapeutics AB publishes annual report for 2018

April 3, 2019 Regulatory
IRLAB Therapeutics AB publicerar årsredovisning för 2018

March 26, 2019 Regulatory
IRLAB Therapeutics AB kallar till årsstämma den 25 april 2019

March 14, 2019
IRLAB adds sites to Phase II study with IRL790 and passes DSMB’s second safety review

March 14, 2019
IRLAB adderar kliniker till Fas II-studie med IRL790 och passerar DSMB:s andra säkerhetsgranskning

February 27, 2019 Regulatory
IRLAB bokslutskommuniké 2018

December 18, 2018
IRLAB provides update on drug candidate IRL790’s clinical program

December 18, 2018
IRLAB uppdaterar om läkemedelskandidaten IRL790s kliniska program

December 6, 2018
Nature’s npj Parkinson’s Disease publishes clinical study with IRLAB’s drug candidate IRL790

December 6, 2018
Natures npj Parkinson’s Disease publicerar klinisk studie med IRLAB:s läkemedelskandidat IRL790

November 22, 2018
A new patent application for IRLAB’s drug candidate IRL752 has been published by World Intellectual Property Organization, WIPO

November 22, 2018
En ny patentansökan för IRLAB:s läkemedelskandidat IRL752 har publicerats av World Intellectual Property Organization, WIPO

November 14, 2018 Regulatory
IRLAB delårsrapport januari – september 2018

October 30, 2018
IRLAB provides in-depth information on results from successful Phase IIa study with IRL752 in Parkinson’s disease

October 30, 2018
IRLAB lämnar fördjupad information om resultat från framgångsrik Fas IIa-studie med IRL752 i Parkinsons sjukdom

September 26, 2018
IRLAB presents ISP at the CNS and Neurodegenerative Targets conference in Boston

September 26, 2018
IRLAB presenterar ISP vid konferensen CNS and Neurodegenerative Targets i Boston

September 20, 2018 Regulatory
Nomination committee appointed in IRLAB

September 20, 2018 Regulatory
Valberedningen i IRLAB utsedd

September 19, 2018 Regulatory
IRLAB nominates two new candidate drugs and updates the pipeline

September 19, 2018 Regulatory
IRLAB utser två nya läkemedelskandidater och uppdaterar projektportföljen

September 11, 2018
IRLAB Receives Notice of Allowance for U.S. Patent

September 11, 2018
IRLAB har erhållit notice of allowance för amerikanskt patent

August 30, 2018 Regulatory
IRLAB reports promising efficacy data from Phase IIa-study with IRL752

August 30, 2018 Regulatory
IRLAB rapporterar lovande effektdata från Fas IIa-studie med IRL752

August 29, 2018 Regulatory
IRLAB delårsrapport januari – juni 2018

June 29, 2018 Regulatory
IRLAB reports top-line results from Phase IIa study with IRL752

June 29, 2018 Regulatory
IRLAB rapporterar ”top-line” resultat från Fas IIa studie med IRL752

May 23, 2018 Regulatory
IRLAB Therapeutics has raised SEK 138.6 million in a directed share issue to top tier investors in the US and Sweden

May 23, 2018 Regulatory
IRLAB Therapeutics har genomfört en riktad nyemission om 138,6 mkr till topprankade investerare i USA och Sverige

May 17, 2018 Regulatory
IRLAB prepares for listing on the Nasdaq Stockholm main market

May 17, 2018 Regulatory
IRLAB förbereder notering på Nasdaq Stockholms huvudlista

May 16, 2018 Regulatory
IRLAB – Resolutions at Annual General Meeting 2018

May 16, 2018 Regulatory
IRLAB – Beslut vid årsstämma 2018

May 16, 2018 Regulatory
IRLAB delårsrapport januari – mars 2018

April 20, 2018 Regulatory
IRLAB Therapeutics AB (publ) publicerar årsredovisning 2017

April 13, 2018 Regulatory
IRLAB Therapeutics AB (publ) kallar till årsstämma den 16 maj 2018

March 12, 2018
International attention on IRLAB’s discovery platform

March 12, 2018
Internationell uppmärksamhet för IRLAB:s forskningsplattform

February 27, 2018 Regulatory
IRLAB Bokslutskommuniké 2017

January 31, 2018
IRLAB update on clinical Phase II pipeline – IRL752 and IRL790

January 31, 2018
IRLAB uppdaterar om pipeline i klinisk fas – mycket goda förutsättningar för fortsatt utveckling av båda läkemedelskandidaterna, IRL752 och IRL790

November 15, 2017 Regulatory
IRLAB receives MHRA approval to conduct Phase II trials with IRL790 in Britain

November 15, 2017 Regulatory
IRLAB får tillstånd att genomföra Fas II-studie med IRL790 i Storbritannien

November 15, 2017 Regulatory
IRLAB delårsrapport januari – september 2017

October 5, 2017 Regulatory
IRLAB receives approval from the Finnish MPA (Fimea)

October 5, 2017 Regulatory
IRLAB erhåller tillstånd från finska läkemedelsverket

October 4, 2017
IRLAB starts Phase II study with IRL752 for the treatment of Parkinson’s disease dementia

October 4, 2017
IRLAB inleder Fas II-studie med IRL752 för behandling av demens vid Parkinsons sjukdom

September 20, 2017 Regulatory
Nomination committee appointed in IRLAB

September 20, 2017 Regulatory
Valberedningen i IRLAB utsedd

August 29, 2017 Regulatory
IRLAB delårsrapport april-juni 2017

August 25, 2017 Regulatory
IRLAB receives approval to initiate Phase II trials with IRL752

August 25, 2017 Regulatory
IRLAB erhåller tillstånd att genomföra Fas II-studie med IRL752

August 17, 2017
IRLAB signs agreement with TCTC to conduct Phase-2 study with IRL790

August 17, 2017 Regulatory
IRLAB signs agreement with TCTC to conduct Phase-2 study with IRL790

August 17, 2017 Regulatory
IRLAB tecknar avtal om Fas 2-studie med IRL790

June 30, 2017 Regulatory
IRLAB utser ny CFO och rekryterar forskare

May 24, 2017 Regulatory
IRLAB patentansöker om storskalig produktionsmetod

May 16, 2017 Regulatory
IRLAB – Beslut vid årsstämma 2017

May 16, 2017 Regulatory
IRLAB Therapeutics delårsrapport jan-mars 2017

May 15, 2017 Regulatory
IRLAB meddelar positiva resultat från studie med IRL790

April 24, 2017 Regulatory
Valberedningens förslag till styrelse i IRLAB Therapeutics AB

April 10, 2017 Regulatory
IRLAB Therapeutics AB (publ) publicerar årsredovisning för 2016

April 10, 2017 Regulatory
IRLAB Therapeutics AB (publ) kallar till årsstämma den 16 maj 2017

March 16, 2017 Regulatory
IRLAB Therapeutics AB (publ) rapporterar positiva resultat från kliniska Fas 1-studier för IRL752 och ingår avtal om att genomföra Fas 2-studier

February 28, 2017
Första handelsdag för IRLAB Therapeutics aktier på First North Premier

February 27, 2017 Regulatory
IRLAB Therapeutics AB (publ) Bokslutskommuniké för 2016

February 14, 2017
IRLAB Therapeutics offentliggör utfall i nyemission – första handelsdag planerad till 28 februari

February 10, 2017
IRLAB Therapeutics AB:s (publ) har godkänts för notering på First North Premier

January 30, 2017
IRLAB Therapeutics inleder teckningsperiod för nyemission inför listning på Nasdaq First North Premier

January 25, 2017
IRLAB Therapeutics ansöker om listning på Nasdaq First North Premier och offentliggör prospekt

January 24, 2017
IRL’s drug discovery platform, the Integrative Screening Process (ISP), and an application, has been published in ACS Chemical Neuroscience

October 13, 2016
IRL receives MPA approval to conduct a 4 week Phase Ib clinical study with IRL790 in patients with Parkinsons disease

February 3, 2016
IRL receives MPA approval and initiates Phase I trials with IRL752, its second compound reaching clinical development

December 14, 2015
IRL receives SEK 4.98 million from Vinnova for Phase I studies with IRL790

October 30, 2015
IRL receives MPA approval to conduct Phase I trials with IRL790, a novel treatment for complications in Parkinson’s disease

October 9, 2015
IRL scientists lead investigation of long term clinical effects of widely prescribed medications in neurodegenerative disorders

May 25, 2015
IRL files new patent application

May 25, 2015
Highly experienced pharma executives join IRL’s Board of Directors

October 21, 2014
IRL secures additional financing

June 23, 2014
IRL receives SEK 3.8 million from VINNOVA